Organon & Co
OGN
View Detailed Chart
7.185USD
+0.095+1.34%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.87BMarket Cap
3.72P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.34%
5 Days
+5.20%
1 Month
-7.17%
6 Months
-28.01%
Year to Date
-51.84%
1 Year
-51.94%
View Detailed Chart
TradingKey Stock Score of Organon & Co
Currency: USD Updated: 2025-12-26Key Insights
Organon & Co's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 84/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 9.36.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Organon & Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Hold
Current Rating
9.357
Target Price
+28.36%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Organon & Co Highlights
StrengthsRisks
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 34.38%.
Undervalued
The company’s latest PE is 3.71, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 219.88M shares, decreasing 14.54% quarter-over-quarter.
Held by Scotia Canadian Dividend Fund
Star Investor Scotia Canadian Dividend Fund holds 44.51K shares of this stock.
Organon & Co News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Organon & Co Info
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Ticker SymbolOGN
CompanyOrganon & Co
CEOMorrissey (Joseph T)
Websitehttps://www.organon.com/
FAQs
What is the current price of Organon & Co (OGN)?
The current price of Organon & Co (OGN) is 7.185.
What is the symbol of Organon & Co?
The ticker symbol of Organon & Co is OGN.
What is the 52-week high of Organon & Co?
The 52-week high of Organon & Co is 17.230.
What is the 52-week low of Organon & Co?
The 52-week low of Organon & Co is 6.180.
What is the market capitalization of Organon & Co?
The market capitalization of Organon & Co is 1.87B.
What is the net income of Organon & Co?
The net income of Organon & Co is 864.00M.
Is Organon & Co (OGN) currently rated as Buy, Hold, or Sell?
According to analysts, Organon & Co (OGN) has an overall rating of Hold, with a price target of 9.357.
What is the Earnings Per Share (EPS TTM) of Organon & Co (OGN)?
The Earnings Per Share (EPS TTM) of Organon & Co (OGN) is 1.934.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%
